The impact of E-cadherin expression on non-small cell lung cancer survival: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 10, 2012, Pages 9621-9628

  Wu, Ying ^a   Liu, Hong Bing ^b   Ding, Ming ^a   Liu, Jian Nan ^a   Zhan, Ping ^c   Fu, Xiao Su ^a   Lu, Gan ^a  

^a Jiangsu Province Geriatric Hospital   (China)

^b NANJING UNIVERSITY   (China)

^c NANJING CHEST HOSPITAL   (China)

Author keywords

E cadherin; Meta analysis; Non small cell lung cancer; Prognosis; Survival

Indexed keywords

UVOMORULIN;

ARTICLE; ASIAN; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ETHNIC DIFFERENCE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; PROPORTIONAL HAZARDS MODELS;

EID: 84868516827     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1827-1     Document Type: Article

References (57)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236. doi:10.3322/caac.20121
2. Reis L, Eisner M, Kosary C (2008) SEER cancer statistics review, 1975-2002. National Cancer Institute, Bethesda
3. Navada S, Lai P, Schwartz A, Kalemkerian G (2006) Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database. J Clin Oncol 24(18 suppl):7082
4. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471-1474
5. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European lung cancer working party. J Clin Oncol 13(5):1221-1230
6. Christofori G (2006) New signals from the invasive front. Nature 441(7092):444-450. doi:10.1038/nature04872
7. Pignatelli M, Vessey CJ (1994) Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 25(9):849-856
8. Goodwin M, Yap AS (2004) Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J Mol Histol 35(8-9):839-844. doi:10.1007/s10735-004-1833-2
9. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2):118-132. doi:10.1038/nrc1276
10. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T (2010) Epithelial-mesenchymal transition in EGFRTKI acquired resistant lung adenocarcinoma. Anticancer Res 30(7):2513-2517
11. Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108(6):2435-2447
12. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M et al (1991) Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139(1):17-23
13. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M (1996) E-cadherin mediated adhesion system in cancer cells. Cancer 77(8 Suppl):1605-1613. doi:10.1002/(SICI) 1097-0142 (1996 0415) 77:8\1605:AID-CNCR28[3.0. CO;2-2
14. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ (1996) Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105(4):394-402
15. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG (1996) Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148(5):1375-1380
16. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M (1999) Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80(9):1366-1372. doi:10.1038/sj.bjc.6690530
17. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A (2010) Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 5(9):1325-1336. doi:10.1097/JTO.0b013e3181e77efc
18. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M (2010) Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 40(7):670-676. doi:10.1093/jjco/hyq041
19. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99(9):1476-1483. doi:10.1038/sj.bjc.6604713
20. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705-719
21. Rothberg BEG, Bracken MB (2006) E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 100(2):139-148. doi:10.1007/s10549-006-9248-2
22. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815-2834
23. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335-371
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188
25. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA (2002) Highthroughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in nonsmallcell lung cancer. J Clin Oncol 20(10):2417-2428
26. Choi YS, Shim YM, Kim SH, Son DS, Lee HS, Kim GY, Han J, Kim J (2003) Prognostic significance of E-cadherin and betacatenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 24(3):441-449
27. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 157(4 Pt 1):1319-1323
28. Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, Constantopoulos SH, Dalavanga Y (2010) Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 138(5):1173-1179. doi:10.1378/chest.10-0157
29. Charalabopoulos K, Gogali A, Dalavaga Y, Daskalopoulos G, Vassiliou M, Bablekos G, Karakosta A, Constantopoulos S (2006) The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 28(1):83-85
30. Ruiz MIG, Floor K, Steinberg SM, Grunberg K, Thunnissen FB, Belien JA, Meijer GA, Peters GJ, Smit EF, Rodriguez JA, Giaccone G (2009) Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 100(1):145-152. doi:10.1038/sj.bjc.6604781
31. Yu J, Shi R, Zhang D, Wang E, Qiu X (2011) Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Archiv 458(1):99-107. doi:10.1007/s00428-010-1016-3
32. Ono K, Uramoto H, Hanagiri T (2010) Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. Anticancer Res 30(9):3273-3278
33. Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA, Yucel N (2011) Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol 47(8):397-402. doi:10.1016/j.arbres.2011.04.010
34. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, Takenoyama M, Hanagiri T, Oyama T, Yasumoto K (2010) Association between lymphangiogenesis-/ micrometastasis-and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70(3):320-328. doi:10.1016/j.lungcan. 2010.02.013
35. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R, Yokomise H (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92(7):1231-1239. doi:10.1038/sj.bjc.6602481
36. Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, Oda M, Watanabe G (2005) Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 130(3):740-745. doi:10.1016/j.jtcvs.2004. 12.051
37. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, Tan D (2004) Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17(4):430-439. doi:10.1038/modpathol.3800041
38. Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Kobayashi S, Kinoshita M, Yokomise H (2003) Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer 88(11):1727-1733. doi:10.1038/sj.bjc.6600955
39. Hirata T, Fukuse T, Naiki H, Wada H (2001) Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin Lung Cancer 3(2):134-140
40. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL (2002) The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 123(3):502-507
41. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000) Expression of E-cadherin and beta-catenin in human nonsmall cell lung cancer and the clinical significance. Clin Cancer Res 6(12):4789-4796
42. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H (2001) E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71(3):949-954 (discussion 954-945)
43. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351-360. doi:10.1056/NEJMoa031644
44. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9):719-727. doi:10.1016/s1470-2045 (06) 70804-x
45. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 120(3):757-766
46. Bohm M, Totzeck B, Birchmeier W, Wieland I (1994) Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis 12(1):55-62
47. Takeichi M (1990) Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 59:237-252. doi:10.1146/annurev. bi.59.070190.001321
48. Kowalski PJ, Rubin MA, Kleer CG (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res BCR 5(6):R217-R222. doi:10.1186/bcr651
49. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K (2010) Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol 25(10):1257-1267
50. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T (2000) Prognostic significance of p53 alterations in patients with nonsmall cell lung cancer: a meta-analysis. Clin Cancer Res 6(10):4055-4063
51. Wang Q, Gu D, Wang M, Zhang Z, Tang J, Chen J (2011) The E-cadherin (CDH1)-160C[A polymorphism associated with gastric cancer among Asians but not Europeans. DNA Cell Biol 30(6):395-400. doi:10.1089/dna.2010.1091
52. Begg CB, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc Ser A 151:419-463
53. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19):9066-9076. doi:10.1158/0008-5472.can-07-0575
54. Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R, Kinch MS (2003) E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes 10(2):105-118
55. Andl CD, Rustgi AK (2005) No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther 4(1):28-31
56. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23(8):1739-1748. doi:10.1038/sj.emboj.7600136
57. Al Moustafa AE, Yen L, Benlimame N, Alaoui-Jamali MA (2002) Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 37(1):49-56